Products

Invitae Genetic Testing
Invitae
Clinical Decision Support & Reference
Invitae, now part of Labcorp, provides comprehensive genetic testing services across many medical specialties, leveraging AI-powered interpretation to offer meaningful insights and support for personalized patient care and diagnosis of hereditary conditions.

See all 1 product →

About Invitae

Invitae Corporation is a medical genetics company that provides genetic information to improve healthcare. Founded in 2010 as a spin-off of Genomic Health, Invitae develops and commercializes Next-Generation Sequencing (NGS)-based sequencing services for the clinical industry. The company’s goal is to aggregate genetic tests into a single, more affordable assay. Invitae offers diagnostic panels that sequence hundreds of genes associated with various conditions, including cardiovascular disease, hereditary cancers, neuromuscular disorders, rare diseases, and pediatric diseases.

Invitae leverages artificial intelligence and machine learning in its operations, particularly for variant interpretation and classification. The company has expanded its capabilities through strategic acquisitions, such as Jungla (an AI-driven biotech company) in 2019, and YouScript, Genelex, and Diploid (which markets AI software for diagnosing genetic disorders) in 2020. Invitae’s services include medical-grade genetic testing, with some services potentially covered by insurance. They offer both diagnostic test kits for specific conditions and proactive test kits to assess predisposition to conditions like cancer and heart disease.

Focus Areas

Genetic testing hereditary cancers rare diseases cardiovascular diseases neurological disorders pharmacogenetics variant interpretation precision oncology digital health reproductive health pediatric genetics

Business Intelligence

TechnologyInvitae Generation™ with Clinical Variant Modeling (machine learning/AI for variant classification), Sherloc (variant classification framework), AI-assisted exome reanalysis, NGS-based sequencing services, digital health platform for genomic and clinical data integration [cite: 9 (from previous turn), 20 (from previous turn), 22 (from previous turn), 28 (from previous turn), 39 (from previous turn)]

What Physicians Need to Know

Specialization
Invitae specializes in a comprehensive suite of genetic tests across various clinical areas, including hereditary cancers, rare diseases, cardiovascular diseases, neurological disorders, pharmacogenetics, precision oncology, reproductive health, and pediatric genetics.
Key Differentiators
Invitae offers a broad diagnostic panel that sequences hundreds of genes, aiming to aggregate genetic tests into a single, more affordable assay. They emphasize actionable genetic information, focusing on conditions that can be prevented or treated with early discovery. Their approach includes customizable test panels, re-requisition options for expanding gene searches at no additional cost, and family testing for VUS resolution. Invitae also provides sponsored, no-charge genetic testing for eligible patients.
Technology Stack
Invitae's technology relies on Next-Generation Sequencing (NGS) for multi-gene panels and exome sequencing. They utilize RNA analysis to supplement hereditary cancer panel results, aiding in VUS classification and detecting novel DNA variants. Their variant classification framework, Sherloc, builds upon the ACMG/AMP guidelines. Invitae also employs bioinformatic tools to detect challenging variants and uses orthogonal methods like PacBio sequencing, Sanger sequencing, array CGH, and MLPA for confirmation of complex findings. For oncology, they offer tumor-informed personalized panel design and proprietary enhanced chemistry for ctDNA detection.
Commitment to Affordability & Access
Invitae is committed to making genetic information accessible and affordable. They work with dedicated billing specialists, offer customizable payment options, and are in-network with most national US health insurance plans, often resulting in out-of-pocket costs under $100 for insured patients. They also have a Financial Assistance Program.
Physician Tip

For physicians, Invitae provides comprehensive genetic testing services designed to streamline workflows and enhance patient care. Their tests offer actionable insights for diagnosis, prognosis, and treatment decisions across a wide range of specialties. Physicians can benefit from customizable test panels, the ability to expand gene searches without additional cost, and family testing for variant resolution. Invitae offers access to board-certified genetic counselors for case review, test selection, result interpretation, and background information on variants, genes, and conditions. They also provide clinical practice resources, patient education materials, and a Genetics Provider Network. The company's EHR integrations, including with Epic Aura, aim to reduce administrative burdens, minimize errors, and provide real-time access to genetic information within the patient's record.

Invitae offers robust Electronic Health Record (EHR) integrations, with over 400 customer EHR integrations completed. Notably, they have a dedicated Epic-certified EHR integration team and utilize Epic Aura (Orders and Results Anywhere Network) for streamlined connectivity with Epic EHR users. These integrations facilitate seamless data transfer of genetic test results, patient demographics, and clinical information, aiming to reduce ordering and results management time, eliminate manual data entry, and enhance data accuracy and interoperability.

Products by Invitae

1 product in the directory

Invitae Genetic Testing
Invitae
Clinical Decision Support & Reference
Invitae, now part of Labcorp, provides comprehensive genetic testing services across many medical specialties, leveraging AI-powered interpretation to offer meaningful insights and support for personalized patient care and diagnosis of hereditary conditions.

What the Web Says

Invitae is a medical genetics company offering a range of genetic testing services for hereditary conditions, cancer, and reproductive health. While their genetic testing is generally considered high-quality and comprehensive, the company has faced significant operational challenges, including filing for bankruptcy in early 2024 and being acquired by Labcorp. This has led to a mixed sentiment among users and employees, with concerns about billing, customer support, and job security.

Overall: Mixed

Strengths

  • High-quality and comprehensive genetic testing for various conditions.
  • Offers genetic counseling services.
  • Privacy-conscious with de-identified data sharing for research.
  • Financial assistance programs available for testing costs.
  • Good work-life balance and positive culture reported by some employees.
  • Competitive pay and benefits for some roles.

Limitations

  • Recent bankruptcy filing and acquisition by Labcorp.
  • Processing errors, delays, and issues with billing and insurance coverage.
  • Customer support issues and lack of responsiveness.
  • Does not test for all relevant genes in certain panels (e.g., TNXB for Classical-like EDS).
  • Job security and advancement concerns among employees.
  • Management issues, including being disconnected from work and lack of cross-company alignment.
  • Some proactive screening tests are not covered by health insurance.

Based on reviews from: Reddit, Indeed.com, Elion Health, Xcode Life (Gene Talk), Nebula Genomics, Nucleus

Last updated: 2026-10-23

Videos

News, demos, and interviews about Invitae.

Loading videos...

Videos load interactively. If none appear, search YouTube for Invitae →

View all on YouTube

Press & Coverage

FDA
FDA Grants First Marketing Authorization for a DNA Test to Assess Predisposition for Dozens of Cancer Types
The FDA granted de novo marketing authorization for the Invitae Common Hereditary Cancers Panel, an in vitro diagnostic test that can help detect genetic variants associated with an elevated risk of developing certain cancers. This is the first broad panel of its kind to receive FDA marketing authorization.
2023-09
BioSpace
Invitae's Common Hereditary Cancers Panel Receives FDA Market Authorization - BioSpace
Invitae announced it gained FDA market authorization for its Common Hereditary Cancers Panel, which is the first broad panel used to identify germline variants associated with hereditary cancer to receive such authorization. The company believes this authorization is a strong vote of confidence in its product and lab quality.
2023-10
MobiHealthNews
Genetic testing company Invitae files for bankruptcy | MobiHealthNews
Invitae filed for Chapter 11 bankruptcy in February 2024, intending to continue operations while seeking to sell its business. The company listed assets of $500 million to $1 billion and liabilities of $1 billion to $10 billion.
2024-02
MedTech Dive
Invitae files for Chapter 11 bankruptcy - MedTech Dive
Invitae filed for Chapter 11 protection in February 2024, with approximately $535 million in assets and $1.62 billion in debts as of September 30. The company aims to keep running and pay down debt through a court-overseen sale.
2024-02
MedTech Dive
Labcorp to acquire Invitae's assets for $239M | MedTech Dive
Labcorp was selected as the winning bidder in the bankruptcy court-supervised sale of Invitae's assets, agreeing to pay $239 million in cash. This acquisition is expected to expand Labcorp's test offerings, particularly in oncology and rare diseases.
2024-04
PR Newswire
Labcorp Finalizes Acquisition of Select Assets of Invitae
Labcorp announced the completion of its acquisition of select assets of Invitae in August 2024. This acquisition aims to expand Labcorp's specialty testing capabilities and its ability to use genetic data to improve clinical trials and treatment regimens in oncology and select rare diseases.
2024-08
PR Newswire
Invitae study shows therapy informed by genetic testing reduces seizures in some patients with epilepsy - PR Newswire
Invitae announced findings from a study published in JAMA Neurology, demonstrating that a positive genetic diagnosis leads to clinical management changes in approximately half of epilepsy patients, and these changes improve health outcomes in as many as three-quarters of patients.
2022-10
Fierce Healthcare
Invitae releases transparency report on how it uses health data - Fierce Healthcare
Invitae released its first data use transparency and impact report, detailing how patient data is used for genetic research. The report highlights Invitae's commitment to transparency and ethical data sharing, with over 3 million tested individuals globally in its database.
2022-12

Frequently Asked Questions

Invitae offers a comprehensive suite of genetic tests, including panels for hereditary cancers like breast, ovarian, prostate, and gastrointestinal cancers, as well as broader genetic risk panels. They also provide testing for various other clinical areas such as cardiology, neurology, rare diseases, metabolic disorders, immunology, and hematology.
Invitae utilizes an evolving approach to variant interpretation, including their proprietary Sherloc system, which refines ACMG-AMP guidelines for consistent and accurate classification. They also employ Clinical Variant Modeling, a machine learning approach that leverages a vast database of patient information to reduce VUS and provide more definitive answers.
Invitae offers extensive clinical support, including access to board-certified genetic counselors for peer-to-peer consultations on test selection, result interpretation, and patient case reviews. They also provide clinical practice resources, patient educational materials, and post-test genetic counseling for patients in the US, US territories, and Canada.
Invitae is committed to making genetic testing affordable and accessible. For insured patients, they bill at contracted rates, and as part of Labcorp, they are in-network with most major health plans. For uninsured patients or those with high out-of-pocket costs, Invitae offers an Enhanced Financial Assistance Program with percentage-based discounts or flat rates (e.g., $250 for cancer panels, $299 for rare disease panels), and provides patient out-of-pocket cost estimates.
Yes, Invitae provides genetic testing for pediatric and rare diseases, including a Neurodevelopmental Disorders Package that combines chromosomal microarray, a neurodevelopmental disorders panel, and Fragile X testing. This can lead to faster diagnoses, inform treatment decisions, identify clinical trial opportunities, and help identify at-risk family members.
Invitae has partnered with Epic through its Aura specialty diagnostics suite to streamline interactions with provider organizations, making test results available within providers' usual workflows. They also engage in research collaborations and genomic health programs with academic institutions, health systems, and commercial organizations to advance genetic testing in healthcare.

Related Companies

A2z Radiology AI is a Boston-based medical imaging AI company that develops software for comprehensive CT interpretation, initially focusing on abdomen-pelvis CT scans. The company’s primary goal is to enhance diagnostic accuracy and efficiency in medical imaging for healthcare providers by leveraging artificial intelligence. Their flagship product, a2z-Unified-Triage, is FDA-cleared radiological computer-aided triage and notification […]

OpenAI is an American artificial intelligence (AI) company that conducts research and develops advanced AI models. While widely known for its generative AI models like ChatGPT and DALL-E, OpenAI has significantly expanded its focus into the healthcare sector. The company’s mission is to ensure that artificial general intelligence (AGI) benefits all of humanity, and this […]

Perimeter Medical Imaging AI is a medical technology company dedicated to transforming cancer surgery through the use of ultra-high-resolution, real-time, advanced imaging tools. The company’s mission is to address significant unmet medical needs in cancer surgery, particularly concerning positive margins and the resulting need for re-excisions. Their proprietary technology, including the S-Series Optical Coherence Tomography […]

Veeva Systems is a global leader in cloud-based software solutions specifically designed for the life sciences industry, including pharmaceutical and biotech companies. The company’s offerings are crucial for managing various aspects of drug development, pharmaceutical manufacturing, and commercial operations. Their platforms help clients navigate complex regulatory requirements, improve operational efficiency, and accelerate the delivery of […]

The University at Buffalo (UB) is a prominent public research university and a flagship institution of the State University of New York (SUNY) system. While UB itself is a broad academic institution, the provided URL (halsted.compbio.buffalo.edu) points to a specific area within UB focused on computational biology. This division is actively engaged in healthcare AI […]

SOPHiA GENETICS is a healthcare AI company that has developed a cloud-native, AI-driven SaaS platform called SOPHiA DDM™. This platform is designed to enable hospitals, clinical laboratories, academic medical centers, and biopharmaceutical companies to analyze and interpret complex genomic, radiomic, and multimodal healthcare data. The company’s mission is to democratize data-driven medicine, providing actionable insights […]

AI Tool Finder
AI-powered search. Results may not be comprehensive.